WEBCAST LINK: H.C. Wainwright BIOCONNECT Virtual Conference
All stakeholders of Alterity Therapeutics, are invited to register to view the Company’s presentation at the H.C. Wainwright BIOCONNEC
Read More
We exist to create an alternate future for people with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory for people living with these debilitating diseases.
First-in-class therapies to treat neurodegenerative disease
Alterity is developing first-in-class therapies to treat neurodegenerative disease. Our lead drug candidate, ATH434, has demonstrated efficacy in several animal models of Parkinsonian disorders and is being evaluated in clinical trials.
News
Alterity Therapeutics Granted New US Patent for Compounds for Neurodegenerative Diseases Including Parkinson’s and Alzheimer’s
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing diseas
Read MoreAlterity Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing diseas
Read MoreFirst Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial
Initiation of Phase 2 Clinical Trial Expected in CY Q1 2022 Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company
Read More
Appendix 4C – Q1 FY22 Quarterly Cash Flow Report
Highlights: New details on ATH34 Phase 2 clinical trial released. Data from bioMUSE presented at International Parkinson and Movement Disord
Read MoreReceive news from Alterity Therapeutics
